DSIP (5mg)

The discovery story is unusual even by peptide standards. Monnier's lab was running cross-circulation experiments, dialyzing blood from rabbits during electrically induced sleep and infusing the dialysate into awake animals, when they noticed the transferred fraction pushed the recipient's EEG toward delta waves, the slow, high-amplitude pattern of deep non-REM sleep. They isolated the active fraction, sequenced it, and published DSIP as a defined nonapeptide in 1977.^[1] The name describes the observed effect, not a confirmed hormone class.

Later structural surveys found DSIP-like immunoreactivity in neurons, peripheral organs, and plasma across several species.^[2] Stress hormone regulation, circadian rhythm, and withdrawal pharmacology all show up in the DSIP literature as a result. None of that breadth resolved what DSIP binds to first.

A 2006 review in the Journal of Neurochemistry, written by two researchers who had studied DSIP for years, is titled plainly: "Delta sleep-inducing peptide (DSIP): a still unresolved riddle."^[3] That title is the honest summary of the field. Decades after the 1977 discovery paper, no study has identified a DSIP-specific receptor, and the peptide's name is now considered something of a misnomer, since some studies find it promotes delta sleep and others don't replicate that effect cleanly.

What is published are downstream observations: shifts in neurotransmitter levels, hormonal changes, altered locomotor and circadian patterns, and modified responses to other neuropharmacological drugs, including withdrawal symptoms.^[3] Researchers designing a DSIP assay are generally not testing a single validated pathway. They're testing one of several candidate effects reported in a literature that never converged on a receptor.

DSIP has an older human clinical record than most catalog peptides. A 1983 case series found delta sleep-inducing peptide eased withdrawal symptoms in patients being weaned from opiates, reasoning it might carry weak agonist activity at opiate receptors.^[4] A 1984 follow-up in European Neurology tested DSIP specifically against alcohol and opiate withdrawal syndromes.^[5] The same 1984 issue carried a separate pilot study using DSIP in patients with chronic, pronounced pain episodes.^[6]

These are small, decades-old European studies, not FDA-reviewed trials, and none of them used the sequence-confirmed reagent grade sold here. Treat them as the historical basis for later interest in DSIP, not as a modern efficacy dataset.

DSIP research didn't stop in the 1980s. A 2018 study in Life Sciences found that a phosphorylated DSIP analog restored spatial memory and CREB phosphorylation in rats whose sleep architecture had been disrupted by simulated high altitude. The memory result and the sleep-quality result came from the same animal model.^[7] A 2021 study in Molecules reported that DSIP improved motor-function recovery in rats after a focal cortical stroke.^[8] A companion 2021 paper in Biomedicines tested a DSIP-like analog called KND. It reduced brain infarct size in mice and myocardial infarct size in rats when given during reperfusion.^[9]

Most recently, a 2024 paper in Frontiers in Pharmacology engineered a DSIP fusion peptide designed to cross the blood-brain barrier and tested it in a PCPA-induced insomnia mouse model.^[10] Read these four papers as a live, active research thread, not a settled conclusion. All four are rodent studies from a small number of labs, and none has an independent Western replication.

A separate line of Russian research looked at DSIP's effect outside the brain entirely. Studies from 2015 and 2016 measured hepatocyte function in rats subjected to restraint stress and foot-shock stress, and found DSIP administration was associated with a protective shift in liver-cell markers compared with stressed, untreated controls.^[11] That's a peripheral-organ stress-response finding, a different endpoint than sleep EEG or infarct volume.

Native DSIP is a short, unmodified nonapeptide, and short peptides generally clear fast and cross the blood-brain barrier inefficiently. A 2017 paper in Protein & Peptide Letters described producing DSIP fused to a protein transduction domain and human serum albumin in Pichia pastoris yeast, an engineering approach aimed at improving delivery and persistence.^[12] The 2024 fusion-peptide insomnia study cited above uses a related strategy.^[10] Those are drug-delivery research programs building on DSIP, not descriptions of the lyophilized reagent sold on this page, which is unmodified, sequence-confirmed DSIP only.

"DSIP peptide 10mg 99% lab tested" and similar search phrases point at the same underlying question: is the purity claim backed by anything. Before treating a supplier as qualified, look at:

• Lot identity: does the listing give a batch or lot number that matches the Certificate of Analysis shipped with the vial, or is the PDF generic or reused across products?
• COA/HPLC traceability: is the COA from an independent third-party lab, reporting purity by area-under-curve HPLC rather than an in-house claim?
• Identity confirmation: does the COA or an accompanying mass-spec report confirm DSIP's nine-residue sequence and molecular weight, not just a purity percentage?
• INN awareness: does the listing recognize emideltide as the same substance, or does it read like a template that's never checked the FDA docket?
• Shipping compliance: does the seller disclose which destinations it won't ship to, rather than leaving that out until checkout?

"How much DSIP to inject," "where to inject DSIP," and "DSIP dosage calculator" are common searches, and this page won't answer any of them. Tetrava Labs doesn't provide human dosing, injection volumes, or administration protocols for DSIP, and a dosing chart built from the small 1980s clinical pilots above wouldn't be a responsible thing to publish as a general recommendation. That's a question for a licensed prescriber operating under a specific compounding pathway, not an RUO catalog listing.

For laboratory use, reconstitute the lyophilized vial under sterile technique with a diluent your protocol specifies, and record diluent lot, concentration, and reconstitution date in your ELN. Match those notes to the batch Certificate of Analysis so identity and purity data stay traceable to the exact vial used in an assay.

DSIP has never been FDA-approved and carries no U.S. drug registration. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptide-related bulk drug substances nominated for the Section 503A Bulks List, the list that lets compounding pharmacies use a substance without a substance-specific approved drug behind it.^[13] DSIP, listed in the docket under emideltide, was one of them.

Six of the seven got a favorable recommendation. DSIP didn't. The committee voted against including it, 6 in favor to 7 opposed with one abstention, the sole rejection of the two-day session.^[14] FDA staff briefing documents cited two specific gaps: no safety data at all for the subcutaneous route DSIP is typically proposed for, and insufficient safety data even for the intravenous route where some data exists.^[15] That's a narrower, more specific finding than a generic "not enough evidence" conclusion.

Committee members who voted against inclusion raised a related point during the hearing: DSIP's clearest supporting human study is from the early 1990s, and the common name has historically covered more than one chemically distinct molecule, which complicates characterization and impurity testing.^[16] That's an advisory vote, not a final rule; the FDA can still act independently through formal rulemaking. It's a materially different regulatory posture than the other six peptides reviewed alongside it, and it doesn't change this catalog listing's status: a Research Use Only laboratory reagent, not a compounding-eligible substance.

DSIP ships as a lyophilized powder, stable at -20°C away from light. Reconstitute under sterile technique with a protocol-appropriate diluent immediately before use, and avoid repeated freeze-thaw cycling once in solution.

Hold reconstituted working solutions at 4°C and use them within the window your laboratory SOP sets. Record diluent lot, reconstitution date, and concentration in your ELN, and match those notes to the batch Certificate of Analysis so identity and purity data stay traceable to the exact vial used in an assay.